Publications by authors named "P Gurugama"
Background: Hereditary angioedema is a rare genetic disease characterized by severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 ().
View Article and Find Full Text PDFBackground: Hereditary angioedema is a rare genetic disease that leads to severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 (), with the goal of lifelong control of angioedema attacks after a single dose.
View Article and Find Full Text PDFArticle Synopsis
- - The survey aimed to gather comprehensive demographic data on hereditary angioedema (HAE) and acquired C1 inhibitor deficiency in the UK to enhance service planning and patient care.
- - A total of 1152 patients with HAE were identified, with a prevalence of 1:59,000 for HAE-1/2 and 1:734,000 for acquired C1 inhibitor deficiency, revealing significant patient demographics and treatment patterns.
- - Findings showed that 45% of HAE patients were on long-term prophylaxis, primarily using danazol, and a significant number had acute treatment supplies available at home, highlighting the need for improved healthcare services for these conditions.
Background: Polyethylene glycol (PEG) is the excipient found in the mRNA COVID-19 vaccines. We previously demonstrated PEG allergy was a cause of severe anaphylaxis to the Pfizer/BioNTech COVID-19 vaccine. PEG is widely used in many household products, cosmetics and medicines.
View Article and Find Full Text PDF